These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34430406)

  • 1. Comprehensive data analysis of genomics, epigenomics, and transcriptomics to identify specific biomolecular markers for prostate adenocarcinoma.
    Ye C; Wang H; Li Z; Xia C; Yuan S; Yan R; Yang X; Ma T; Wen X; Yang D
    Transl Androl Urol; 2021 Jul; 10(7):3030-3045. PubMed ID: 34430406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of prognostic markers in sarcomas base on a multi-omics analysis.
    Song Y; Yang K; Sun T; Tang R
    BMC Med Genomics; 2021 Jan; 14(1):31. PubMed ID: 33509178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    Zhao Y; Gao Y; Xu X; Zhou J; Wang H
    BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis at epigenomics and transcriptomics levels reveals prognostic subtypes of lung squamous cell carcinoma.
    Xu Y; She Y; Li Y; Li H; Jia Z; Jiang G; Liang L; Duan L
    Biomed Pharmacother; 2020 May; 125():109859. PubMed ID: 32036209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune infiltration phenotypes of prostate adenocarcinoma and their clinical implications.
    Ma Z; Cheng X; Yue T; Shangguan X; Xin Z; Zhang W; Pan J; Wang Q; Xue W
    Cancer Med; 2021 Aug; 10(15):5358-5374. PubMed ID: 34128342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.
    Zheng M; Hu Y; Gou R; Wang J; Nie X; Li X; Liu Q; Liu J; Lin B
    Aging (Albany NY); 2019 Jun; 11(12):4198-4215. PubMed ID: 31257224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Genomic and Epigenomic Analyses on Transcriptomic Regulation in Stomach Adenocarcinoma.
    Chen J; Liu W; Du J; Wang P; Wang J; Ye K
    Front Genet; 2021; 12():778095. PubMed ID: 35222516
    [No Abstract]   [Full Text] [Related]  

  • 8. A N
    Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L
    J Oncol; 2022; 2022():8604216. PubMed ID: 35602299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenomic and genomic analysis of transcriptome modulation in skin cutaneous melanoma.
    Chen W; Cheng P; Jiang J; Ren Y; Wu D; Xue D
    Aging (Albany NY); 2020 Jul; 12(13):12703-12725. PubMed ID: 32639949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
    Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
    Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma.
    Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y
    Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of genomic, epigenomic and transcriptomic data identified molecular subtypes of esophageal carcinoma.
    Ma M; Chen Y; Chong X; Jiang F; Gao J; Shen L; Zhang C
    Aging (Albany NY); 2021 Feb; 13(5):6999-7019. PubMed ID: 33638948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-omics analysis based on integrated genomics, epigenomics and transcriptomics in pancreatic cancer.
    Kong L; Liu P; Zheng M; Xue B; Liang K; Tan X
    Epigenomics; 2020 Mar; 12(6):507-524. PubMed ID: 32048534
    [No Abstract]   [Full Text] [Related]  

  • 14. A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
    Wang X; Zhou B; Xia Y; Zuo J; Liu Y; Bi X; Luo X; Zhang C
    BMC Cancer; 2021 Jul; 21(1):801. PubMed ID: 34247575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
    Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
    Front Immunol; 2021; 12():723172. PubMed ID: 34539658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Expression of PDLIM2 Predicts a Poor Prognosis in Prostate Cancer and Is Correlated with Epithelial-Mesenchymal Transition and Immune Cell Infiltration.
    Piao S; Zheng L; Zheng H; Zhou M; Feng Q; Zhou S; Ke M; Yang H; Wang X
    J Immunol Res; 2022; 2022():2922832. PubMed ID: 35707002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis and experimental validation of the value of monocyte-associated features in prostate cancer prognosis and immunotherapy.
    Wang Y; Li C; He J; Zhao Q; Zhou Y; Sun H; Zhu H; Ding B; Ren M
    Front Immunol; 2024; 15():1426474. PubMed ID: 38947325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated Analysis of Multiomics Data Identified Molecular Subtypes and Oxidative Stress-Related Prognostic Biomarkers in Glioblastoma Multiforme.
    Ma Y; Xi Z
    Oxid Med Cell Longev; 2022; 2022():9993319. PubMed ID: 36193073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of Molecular Subtype and Prognostic Signature for Prostate Adenocarcinoma based on Neutrophil Extracellular Traps.
    Zheng Y; Sun H; Yang S; Liu W; Jiang G
    J Cancer; 2024; 15(9):2678-2690. PubMed ID: 38577608
    [No Abstract]   [Full Text] [Related]  

  • 20. A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.
    Ye C; Qin S; Qiu S; Zhao L; Miao J; Chen Y; Zhou T
    Transl Androl Urol; 2022 Dec; 11(12):1691-1705. PubMed ID: 36632155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.